Growth differentiation factor 15 can distinguish between hypertrophic cardiomyopathy and hypertensive hearts

Heart and Vessels

Volumn 29, Issue 2, 2014, Pages 231-237

  Hanatani, Shinsuke ^a   Izumiya, Yasuhiro ^a   Takashio, Seiji ^a   Kojima, Sunao ^a   Yamamuro, Megumi ^a   Araki, Satoshi ^a   Rokutanda, Taku ^a   Tsujita, Kenichi ^a   Yamamoto, Eiichiro ^a   Tanaka, Tomoko ^a   Tayama, Shinji ^a   Kaikita, Koichi ^a   Hokimoto, Seiji ^a   Sugiyama, Seigo ^a   Ogawa, Hisao ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

Author keywords

Biomarker; Cytokine; Heart failure; Hypertension

Indexed keywords

ACETYLSALICYLIC ACID; ALDOSTERONE ANTAGONIST; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GROWTH DIFFERENTIATION FACTOR 15; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LOOP DIURETIC AGENT; THIAZIDE DIURETIC AGENT; BIOLOGICAL MARKER; GDF15 PROTEIN, HUMAN;

ADULT; AGE; AGED; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORRELATION ANALYSIS; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLOMERULUS FILTRATION RATE; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSIVE LEFT VENTRICULAR HYPERTROPHY; HYPERTROPHIC CARDIOMYOPATHY; MAJOR CLINICAL STUDY; MALE; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; SEX; BLOOD; CARDIOMYOPATHY, HYPERTROPHIC; CASE CONTROL STUDY; COMPARATIVE STUDY; COMPLICATION; DIFFERENTIAL DIAGNOSIS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PREDICTIVE VALUE; PROGNOSIS; STATISTICAL MODEL;

AGED; AREA UNDER CURVE; BIOMARKERS; CARDIOMYOPATHY, HYPERTROPHIC; CASE-CONTROL STUDIES; DIAGNOSIS, DIFFERENTIAL; FEMALE; GROWTH DIFFERENTIATION FACTOR 15; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NATRIURETIC PEPTIDE, BRAIN; ODDS RATIO; PREDICTIVE VALUE OF TESTS; PROGNOSIS; ROC CURVE;

EID: 84897021820     PISSN: 09108327     EISSN: 16152573     Source Type: Journal    
DOI: 10.1007/s00380-013-0337-y     Document Type: Article

References (29)

1. Misawa K, Nitta Y, Matsubara T, Oe K, Kiyama M, Shimizu M, Mabuchi H (2002) Difference in coronary blood flow dynamics between patients with hypertension and those with hypertrophic cardiomyopathy. Hypertens Res 25:711-716 (Pubitemid 35153759)
2. Maron BJ (2002) Hypertrophic cardiomyopathy: a systematic review. JAMA 287:1308-1320
3. Frohlich ED, Apstein C, Chobanian AV, Devereux RB, Dustan HP, Dzau V, Fauad-Tarazi F, Horan MJ, Marcus M, Massie B, Pfeffer MA, Re RN, Roccella EJ, Savage D, Shub C (1992) The heart in hypertension. N Engl J Med 327:998-1008
4. Toshima H, Koga Y, Yoshioka H, Akiyoshi T, Kimura N (1975) Echocardiographic classification of hypertensive heart disease. A correlative study with clinical features. Jpn Heart J 16:377-393
5. Bahler AS, Teichholz LE, Gorlin R, Herman MV (1977) Correlations of electrocardiography and echocardiography in determination of left ventricular wall thickness: study of apparently normal subjects. Am J Cardiol 39:189-195 (Pubitemid 8043833)
6. Dunn FG, Chandraratna P, deCarvalho JG, Basta LL, Frohlich ED (1977) Pathophysiologic assessment of hypertensive heart disease with echocardiography. Am J Cardiol 39:789-795 (Pubitemid 8120482)
7. Shapiro LM, McKenna WJ (1983) Distribution of left ventricular hypertrophy in hypertrophic cardiomyopathy: a two-dimensional echocardiographic study. J Am Coll Cardiol 2:437-444 (Pubitemid 13050018)
8. Bootcov MR, Bauskin AR, Valenzuela SM, Moore AG, Bansal M, He XY, Zhang HP, Donnellan M, Mahler S, Pryor K, Walsh BJ, Nicholson RC, Fairlie WD, Por SB, Robbins JM, Breit SN (1997) MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-beta superfamily. Proc Natl Acad Sci USA 94:11514-11519 (Pubitemid 27451030)
9. Hsiao EC, Koniaris LG, Zimmers-Koniaris T, Sebald SM, Huynh TV, Lee SJ (2000) Characterization of growth-differentiation factor 15, a transforming growth factor beta superfamily member induced following liver injury. Mol Cell Biol 20:3742-3751 (Pubitemid 30243919)
10. Schober A, Böttner M, Strelau J, Kinscherf R, Bonaterra GA, Barth M, Schilling L, Fairlie WD, Breit SN, Unsicker K (2001) Expression of growth differentiation factor-15/macrophage inhibitory cytokine-1 (GDF-15/MIC-1) in the perinatal, adult, and injured rat brain. J Comp Neurol 439:32-45
11. Kempf T, Eden M, Strelau J, Naguib M, Willenbockel C, Tongers J, Heineke J, Kotlarz D, Xu J, Molkentin JD, Niessen HW, Drexler H, Wollert KC (2006) The transforming growth factor-beta superfamily member growth-differentiation factor-15 protects the heart from ischemia/reperfusion injury. Circ Res 98:351-360
12. Kempf T, Zarbock A, Widera C, Butz S, Stadtmann A, Rossaint J, Bolomini-Vittori M, Korf-Klingebiel M, Napp LC, Hansen B, Kanwischer A, Bavendiek U, Beutel G, Hapke M, Sauer MG, Laudanna C, Hogg N, Vestweber D, Wollert KC (2011) GDF-15 is an inhibitor of leukocyte integrin activation required for survival after myocardial infarction in mice. Nat Med 17:581-588
13. Xu J, Kimball TR, Lorenz JN, Brown DA, Bauskin AR, Klevitsky R, Hewett TE, Breit SN, Molkentin JD (2006) GDF15/MIC-1 functions as a protective and antihypertrophic factor released from the myocardium in association with SMAD protein activation. Circ Res 98:342-350
14. Wollert KC, Kempf T, Peter T, Olofsson S, James S, Johnston N, Lindahl B, Horn-Wichmann R, Brabant G, Simoons ML, Armstrong PW, Califf RM, Drexler H, Wallentin L (2007) Prognostic value of growth-differentiation factor-15 in patients with non-ST-elevation acute coronary syndrome. Circulation 115:962-971 (Pubitemid 46328289)
15. Kempf T, von Haehling S, Peter T, Allhoff T, Cicoira M, Doehner W, Ponikowski P, Filippatos GS, Rozentryt P, Drexler H, Anker SD, Wollert KC (2007) Prognostic utility of growth differentiation factor-15 in patients with chronic heart failure. J Am Coll Cardiol 50:1054-1060 (Pubitemid 47348231)
16. Stahrenberg R, Edelmann F, Mende M, Kockskämper A, Düngen HD, Lüers C, Binder L, Herrmann-Lingen C, Gelbrich G, Hasenfuss G, Pieske B, Wachter R (2010) The novel biomarker growth differentiation factor 15 in heart failure with normal ejection fraction. Eur J Heart Fail 12:1309-1316
17. Eitel I, Blase P, Adams V, Hildebrand L, Desch S, Schuler G, Thiele H (2011) Growth-differentiation factor 15 as predictor of mortality in acute reperfused ST-elevation myocardial infarction: insights from cardiovascular magnetic resonance. Heart 97:632-640
18. Lind L, Wallentin L, Kempf T, Tapken H, Quint A, Lindahl B, Olofsson S, Venge P, Larsson A, Hulthe J, Elmgren A, Wollert KC (2009) Growth- differentiation factor-15 is an independent marker of cardiovascular dysfunction and disease in the elderly: results from the Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) Study. Eur Heart J 30:2346-2353
19. Wang X, Yang X, Sun K, Chen J, Song X, Wang H, Liu Z, Wang C, Zhang C, Hui R (2010) The haplotype of the growth-differentiation factor 15 gene is associated with left ventricular hypertrophy in human essential hypertension. Clin Sci (Lond) 118:137-145
20. Xue H, Fu Z, Chen Y, Xing Y, Liu J, Zhu H, Zhou X (2012) The association of growth differentiation factor-15 with left ventricular hypertrophy in hypertensive patients. PLoS ONE 7:e46534-e46539
21. Montoro-García S, Hernández-Romero D, Jover E, García-Honrubia A, Vilchez JA, Casas T, Martínez P, Climent V, Caballero L, Valdés M, Marín F (2012) Growth differentiation factor-15, a novel biomarker related with disease severity in patients with hypertrophic cardiomyopathy. Eur J Intern Med 23:169-174
22. Hen Y, Iguchi N, Machida H, Takada K, Utanohara Y, Sumiyoshi T (2012) High signal intensity on T2-weighted cardiac magnetic resonance imaging correlates with the ventricular tachyarrhythmia in hypertrophic cardiomyopathy. Heart Vessels. doi:10.1007/S00380-012-0300-3
23. Tanaka M, Fujiwara H, Onodera T, Wu DJ, Hamashima Y, Kawai C (1986) Quantitative analysis of myocardial fibrosis in normals, hypertensive hearts, and hypertrophic cardiomyopathy. Br Heart J 55:575-581 (Pubitemid 16092908)
24. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise JS, Solomon SD, Spencer KT, Sutton MS, Stewart WJ (2005) Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 18:1440-1463 (Pubitemid 41821197)
25. Sadanaga T, Mitamura H, Kohsaka S, Ogawa S (2012) Steady-state B-type natriuretic peptide levels in patients with atrial fibrillation of various clinical backgrounds. Heart Vessels 27:280-286
26. Cuspidi C, Meani S, Fusi V, Valerio C, Catini E, Sala C, Sampieri L, Magrini F, Zanchetti A (2005) Prevalence and correlates of left atrial enlargement in essential hypertension: role of ventricular geometry and the metabolic syndrome: the Evaluation of Target Organ Damage in Hypertension study. J Hypertens 23:875-882 (Pubitemid 40523288)
27. Yu CM, Sanderson JE, Marwick TH, Oh JK (2007) Tissue Doppler imaging a new prognosticator for cardiovascular diseases. J Am Coll Cardiol 49:1903-1914 (Pubitemid 46711162)
28. Ogino K, Ogura K, Kinugawa T, Osaki S, Kato M, Furuse Y, Kinugasa Y, Tomikura Y, Igawa O, Hisatome I, Shigemasa C (2004) Neurohumoral profiles in patients with hypertrophic cardiomyopathy: differences to hypertensive left ventricular hypertrophy. Circ J 68:444-450 (Pubitemid 38657533)
29. Maron BJ, Tholakanahalli VN, Zenovich AG, Casey SA, Duprez D, Aeppli DM, Cohn JN (2004) Usefulness of B-type natriuretic peptide assay in the assessment of symptomatic state in hypertrophic cardiomyopathy. Circulation 109:984-989 (Pubitemid 38282851)